Welcome to our dedicated page for Dyadic Intl Del SEC filings (Ticker: DYAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Dyadic International, Inc. filings document the regulatory disclosures of a Nasdaq-listed biotechnology company developing and commercializing recombinant proteins and enzymes through proprietary microbial expression platforms. Form 8-K reports cover financial results, press-release exhibits, business-development updates, and Nasdaq continued-listing matters affecting the company's common stock.
The filing record also includes material agreements and capital-structure disclosures, including equity issuance programs under shelf registration statements, underwriting arrangements for common stock offerings, and amendments to security agreements tied to senior secured convertible promissory notes. These documents describe Dyadic's governance, registered securities, financing activity, listing compliance, and formal event reporting.
Dyadic International, Inc., now doing business as Dyadic Applied BioSolutions, files its annual report describing its shift from a research-focused company to a commercially oriented biotechnology business built on its proprietary C1 and Dapibus™ microbial protein production platforms.
The company targets non-therapeutic applications in life sciences, food and nutrition, and bio‑industrial markets, supported by partnerships with Proliant, Fermbox, Inzymes and BRIG BIO, and funded collaborations with groups such as the Gates Foundation and CEPI. Dyadic estimates a combined addressable market of over $25 billion across its core segments.
As of December 31, 2025, Dyadic had five full‑time employees and an accumulated deficit of about $93.5 million, with a significant share of revenue concentrated in two customers. The filing highlights extensive risk factors, including continued losses, reliance on third parties, regulatory uncertainty and intense competition from established expression systems and alternative technologies.
Dyadic International, Inc. entered into an at-the-market equity offering program that allows it to sell shares of its common stock with an aggregate offering price of up to $4,237,818 through Craig-Hallum Capital Group LLC as sales agent.
Sales can be made from time to time under an existing Form S-3 shelf and a new prospectus supplement, using methods such as ordinary broker transactions, block trades, and negotiated deals at market-related prices. Dyadic is not required to sell any shares and can suspend or terminate the program at any time. Craig-Hallum will receive up to 3.0% of the gross sales price as compensation, and Dyadic will reimburse certain expenses and provide customary indemnification.
Dyadic International, Inc. has filed a prospectus supplement to offer up to $4,237,818 of common stock in an at-the-market offering through Craig-Hallum Capital Group LLC as sales agent.
The sales agreement permits sales from time to time at prevailing market prices, with Craig-Hallum paid up to 3.0% commission. The prospectus supplement notes the public float calculation that limits sales under Form S-3 to one-third of public float and explains that Dyadic previously sold $5,749,400 in the prior 12 months, leaving an available capacity of $4,237,818 under the applicable instruction.
Dyadic International Inc. filed an amended Schedule 13G showing that Mark A. Emalfarb beneficially owns 6,675,439 shares of Dyadic common stock, representing 17.5% of the class based on 36,187,798 shares outstanding as of December 31, 2025.
The position includes 993,000 shares underlying presently exercisable options, 4,730,058 shares held through the MAE Trust, and 952,381 shares underlying an 8.0% Senior Secured Convertible Promissory Note due December 31, 2027, convertible at $1.05 per share. Emalfarb has sole voting and dispositive power over all reported shares through his role as sole trustee and beneficiary of the MAE Trust.
Dyadic International CFO Rawson Ping Wang reported equity compensation on Form 4. On January 2, 2026, Wang acquired 29,158 shares of common stock at $0, representing stock issued upon vesting of RSUs granted as a key employee annual bonus in lieu of a cash bonus earned for the year ended 2025. These RSUs vested in full upon grant, bringing Wang’s directly held common stock to 170,151 shares after the transaction.
On the same date, Wang also received an annual grant of 47,250 stock options with an exercise price of $0.94 per share. This option expires on January 2, 2036 and vests in four equal installments beginning on the first anniversary of the grant date, contingent on continued service to Dyadic International.
Dyadic International director Jack Kaye reported several equity transactions on January 2, 2026. He exercised 21,552 restricted stock units, receiving the same number of common shares at $0 per share, bringing his directly held common stock to 81,201 shares. The exercised units came from awards that vested after one year of board service and were settled fully in common stock.
On the same date, Kaye received an annual grant of 67,500 stock options with a $0.94 exercise price, exercisable starting January 2, 2027 and expiring January 2, 2036. He also received an annual grant of 39,894 restricted stock units, each representing a right to one share of common stock, scheduled to be settled entirely in shares when they vest, subject to continued board service.
Dyadic International director Seth Herbst reported equity compensation changes. On January 2, 2026, 21,552 restricted stock units were converted into the same number of shares of Dyadic common stock at a price of $0 per share, increasing his directly held common stock to 202,311 shares.
On the same date, Herbst received an annual grant of 50,000 stock options with an exercise price of $0.94 per share, exercisable from January 2, 2027 until January 2, 2036. He was also granted 39,894 restricted stock units, which the disclosure explains will be settled 100% in Dyadic common stock when they vest on the first anniversary of the grant date, subject to his continued service on the board.
Dyadic International, Inc. reported that it received a Nasdaq deficiency notice on December 19, 2025 because its common stock failed to maintain the required minimum bid price of $1 per share for 30 consecutive business days under Nasdaq Listing Rule 5550(a)(2). The notice does not immediately affect trading of the shares on the Nasdaq Capital Market.
The company has 180 calendar days, until June 17, 2026, to regain compliance by having its bid price close at or above $1 per share for at least 10 consecutive business days. If it does not regain compliance by that date, Dyadic may qualify for an additional 180-day grace period if it meets other initial listing standards and notifies Nasdaq of its plan to cure the deficiency. Otherwise, its shares could be subject to delisting, though Dyadic would have the right to appeal. The company states it plans to actively monitor its share price and evaluate options to address the issue.
Dyadic International (DYAI) filed its Q3 2025 report, showing lower revenue and a wider loss as it shifts toward commercial applications of its Dapibus and C1 protein platforms. Total revenue was $1,164,617 for the quarter (vs. $1,957,500 a year ago), driven by grant revenue and research services. Net loss was $1,976,012 (vs. $203,460), or $0.06 per share, as operating expenses and grant-related costs rose.
Liquidity improved with financing and awards. On August 1, the company completed an underwritten offering of 6,052,000 shares at $0.95, generating $4.9 million in net proceeds. As of September 30, 2025, Dyadic reported cash, cash equivalents, restricted cash and investments totaling about $10.4 million, and stated these resources are expected to cover at least the next 12 months. The company continued execution under a $3.09 million Gates Foundation grant and a CEPI award under which Dyadic may receive up to $2.4 million as a subcontractor.
Convertible notes issued in March 2024 remain outstanding at 8% interest, with a $1.40 conversion price set by amendment; a related trust purchased $1.0 million of the notes in September. Shares outstanding were 36,187,798 as of November 11, 2025.
Dyadic International, Inc. filed an 8-K describing two key updates. First, the company furnished a press release highlighting recent milestone achievements and business developments.
More importantly, Dyadic reports it has regained full compliance with Nasdaq listing standards. Its market value of listed securities was at least $35 million for 10 consecutive business days from September 16 to September 30, 2025, satisfying Nasdaq Listing Rule 5550(b)(2). In addition, its common stock maintained a closing bid price of at least $1.00 per share for 10 consecutive business days from September 19 to October 2, 2025, restoring compliance with Nasdaq Listing Rule 5550(a)(2) and closing prior deficiency matters.